Bioaffinity Technologies Inc

This proposal requests shareholder approval for the issuance of up to 271,500 shares upon exercise of the August 2025 Warrants, a vote required under Nasdaq Listing Rule 5635(d) because the potential issuance may equal or exceed 20% of pre-offering outstanding common stock. Management frames the request as enabling the company to permit warrant holders to exercise their warrants — in cash or cashless (if registration is not effective) — and to realize up to approximately $2.9 million in gross proceeds at the initial $10.56 exercise price, which supports operations. The company emphasizes that the Private Placement and related inducement transactions have already closed and that this vote only authorizes the issuance upon exercise. If the proposal fails, the company cannot permit warrant exercises and would likely incur additional costs and face potential liquidity shortfalls that could impair operations. Approval risks dilution to existing shareholders and potential downward pressure on the market price as new shares could be sold into the market, and the company clearly discloses those dilutionary effects. The Board recommends approval as a capital-raising and compliance step designed to preserve funding options and to fulfill agreements with warrant holders and Nasdaq rules. From a governance perspective, the transaction is time-sensitive given contractual obligations to holders and Nasdaq compliance; the board presents it as necessary to avoid repeated shareholder meetings and incremental costs. An analyst should weigh the immediate balance-sheet benefit of potential proceeds and the company’s use of proceeds against the near-term dilution and the possibility of future exercise-price resets under related proposals. Overall, approval facilitates access to committed financing embodied in the warrants while imposing clear dilutionary trade-offs for existing holders.

This proposal asks shareholders to approve an anti-dilution adjustment embedded in the August 2025 Warrants that would reset the warrant exercise price downward (subject to a $4.50 floor) and increase the number of shares issuable upon exercise so that aggregate proceeds from the warrants remain constant post-reset, potentially increasing maximum issuable shares to 365,620 if a Dilutive Issuance occurs. Management states the request is required to comply with Nasdaq Rule 5635(d) and the language of the Purchase Agreement and Inducement Agreement; without approval the company may face contractual breach consequences and recurring shareholder meetings. The adjustment functions as a traditional full-ratchet-like protection against subsequent financings priced below the then-current warrant exercise price, although the company describes a formulaic reset that preserves aggregate economic proceeds to the warrant holders. Approval would materially increase potential dilution beyond the 271,500 base warrant shares and could significantly expand share overhang if low-priced financings occur, which investors should treat as a substantive future dilution risk. The company represents that holders cannot exercise beyond ownership caps and that certain purchasers will be excluded from registration coverage for Anti-Dilution Adjustment shares, limiting resale options for some holders. Management frames the approval as a necessary step to maintain financing flexibility and contractual compliance, while acknowledging the adverse dilutive consequences for existing shareholders and market price pressure. From an analytical standpoint, the governance calculation weighs fulfilling financing commitments and avoiding legal/operational disruption against shareholder dilution; an investor should model dilution scenarios and timing (e.g., whether a Dilutive Issuance is probable) before supporting the measure. The Board recommends approval to preserve the company’s ability to consummate financings and honor inducement terms, but approval materially changes capital structure risk that must be monitored.

This proposal seeks shareholder approval for an anti-dilution adjustment applicable to the Series B Convertible Preferred Stock issued in the August 2025 private placement, which would reduce the conversion price (subject to a $3.00 floor) in the event of a Dilutive Issuance and proportionally increase the number of conversion shares up to an additional 131,884 shares. Management frames the request as necessary to comply with Nasdaq Listing Rule 5635(d) and the Purchase Agreement’s anti-dilution mechanics; failure to obtain approval would trigger repeated shareholder meetings and potential contractual non-compliance costs. The adjustment effectively protects preferred holders from subsequent lower-priced issuances, preserving their economic position at the expense of increased dilution for common shareholders; the company discloses both the mechanics and the cap on additional shares. For investors, the key tradeoffs are preserving the company’s ability to secure financing and honoring investor commitments versus the downside of issuing a material number of additional common shares under adverse pricing. The Board notes safeguards such as ownership caps limiting conversions by any holder to 4.99% (or up to 9.99% upon election), but the aggregate dilutive effect could be meaningful given the company’s small share base. The proposal is administrative in nature relative to the private placement’s existing economics but substantively changes potential future share issuance exposure and liquidity. Analysts should assess the likelihood and timing of Dilutive Issuances and model how additional conversion shares would affect ownership, EPS, and potential future financing needs. The Board recommends approval to satisfy contractual obligations and Nasdaq rules, while existing shareholders bear the risk of increased overhang and dilution.

This management proposal requests shareholder approval to expand the 2024 Equity Incentive Plan pool from 66,666 to 1,000,000 shares, representing roughly 20% of the company’s fully diluted capital base as of the record date, to support future grants to employees, directors, and consultants. Management argues the increase is necessary to attract, retain, and incentivize talent and that the requested amount, together with remaining shares, should cover anticipated grants for about two years. The company describes governance controls: the plan administrator (Board or committee) will oversee awards, cannot reprice awards without shareholder approval, and will apply equitable adjustments on corporate transactions. Dilution is acknowledged; management weighed dilution against competitive market practices and historical run rates when determining the pool size. For shareholders, the primary concerns are dilution magnitude and alignment of equity awards with performance; the plan includes limitations on counting certain awards and Exempt Awards that do not count against the limit. The Board recommends approval, emphasizing that equity compensation is central to retention in a competitive diagnostics and life sciences sector and that denying the increase would constrain the company’s ability to execute its strategy. Analysts should evaluate historical share usage, award pacing, expected grant recipients, and whether compensation policies provide measurable performance alignment to justify the increase. From a governance standpoint, the plan’s anti-repricing clause and committee oversight are positives, but the size of the increase materially expands potential dilution and should be modeled against projected value creation from hires and retention benefits.

This proposal asks shareholders to pre-approve potential non-public offerings of up to 10 million shares (subject to reverse split adjustments) or securities convertible into such shares, with gross proceeds capped at $10 million and a maximum discount of up to 35% to market, to be used for capital raising through March 31, 2026. Management frames the request as prudential: given market volatility and the company’s limited float, pre-approval offers operational agility to execute financings quickly when attractive investor interest or strategic opportunities arise. The stated caps and discount limitation are attempts to balance fundraising flexibility against shareholder dilution, although a 35% discount is material and reflects the small float and higher execution risk. Approval could concentrate ownership if large blocks are purchased by few investors, potentially changing control dynamics and governance outcomes, which the company discloses as an anti-takeover concern. The Board underscores that no specific underwriting arrangements are in place; the authority is permissive and subject to Board judgment on terms. From an analyst viewpoint, the proposal’s value depends on the company’s near-term cash needs, alternative financing options, and likelihood of execution at better-than-disclosed maximum discount levels. Investors should consider the trade-off between preserving liquidity runway versus dilution and potential concentration of voting power. The Board recommends approval to preserve optionality for capital raising, but shareholders should require transparency on any subsequent transactions and consider potential governance impacts.

This proposal seeks shareholder approval to permit any change in control consequences under Nasdaq Marketplace Rule 5635(b)/(d) that could arise from the non-public offerings contemplated in Proposal 7, recognizing that Nasdaq guidance treats transfers resulting in a person owning 20% or more of outstanding voting power as a change of control for listing rule purposes. Management argues the approval is procedural and tailored to Nasdaq compliance, enabling the company to proceed with financings that might otherwise require separate, time-consuming shareholder votes. The practical effect is to pre-clear scenarios where a financing investor could cross Nasdaq’s 20% threshold, which helps expedite capital formation but may enable substantial ownership concentration without additional shareholder consent at the time of the deal. The company notes that this approval is limited to Nasdaq rule treatment and does not change Delaware law or charter/bylaw requirements outside of Nasdaq’s rule framework. For investors and governance analysts, the main concerns are the potential for sudden shifts in voting power and control dynamics if large placements are executed; the Board discloses these risks and preserves discretion on transaction terms. The board recommends approval to maintain financing flexibility, but shareholders should monitor any such transactions closely and assess counterparties, protections for minority shareholders, and any governance changes accompanying large investments. Approval is pragmatic from a listing compliance standpoint but may have meaningful strategic implications depending on who acquires the position and the associated agreements.

This proposal asks shareholders to authorize a broad-range reverse stock split (1-for-2 up to 1-for-250) that the Board may elect to implement to increase the per-share trading price, primarily to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement and to enhance perceived marketability. Management positions the split as a tool to attract institutional investors, reduce volatility associated with low-priced stocks, and facilitate capital raising; it also notes secondary effects such as increasing the number of available authorized but unissued shares for future issuance. A reverse split will not change a shareholder’s percentage ownership (ignoring fractional-share cash-outs), but it will increase the nominal exercise prices and adjust outstanding options/warrants and reserved plan shares proportionally while potentially creating odd lot holdings and fractional-share cash payments. The Board retains discretion whether and when to implement the split (and the exact ratio) within the authorized range, and approval will expire after one year if not used, which limits permanent change unless acted upon. From a governance lens, the wide range grants significant discretion to management which can be useful tactically but reduces shareholder control over the exact ratio chosen; investors should note that the Board can elect smaller or larger ratios depending on market conditions. The principal downside is potential reduced liquidity from fewer outstanding shares and the perceptional stigma that a reverse split can signal weakness; conversely, success depends on whether the market sustains a higher price post-split. The Board recommends approval to preserve remedial options to maintain Nasdaq listing and to support capital markets activity, but shareholders should expect careful managerial justification and public disclosure if the Board elects to implement any split within the authorized range.

This proposal requests shareholder authorization to permit the meeting to be adjourned or postponed to allow further solicitation of votes if there are insufficient votes to approve certain material proposals (notably Proposals 3–9). Management frames the adjournment power as a standard procedural mechanism to ensure that the Board can continue to seek the necessary approvals and reduce the administrative burden and costs of reconvening multiple special meetings. The practical effect is that proxies authorized to vote for adjournment may enable the company to continue outreach and negotiate additional support without rerunning a full proxy solicitation at each failed vote. From a governance viewpoint, while adjournment authority is common and pragmatic, it can extend the period of uncertainty for shareholders and leave material corporate actions pending for longer periods, potentially affecting market perception and strategic execution. The Board discloses that adjournment votes require a majority of shares present or represented and that abstentions count as votes against, aligning incentives for solicitation. Analysts should monitor whether adjournment is used defensively to pressure votes or legitimately to secure sufficient participation for Nasdaq-ruled approvals; transparency around subsequent solicitations is important. The Board recommends approval to ensure flexibility and to conserve resources in seeking votes necessary to execute the company’s financing and corporate governance plans.